NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Ernexa Therapeutics Inc. (ERNA) Stock Analysis

Ernexa Therapeutics Inc. (ERNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ERNA

$4.31

−$0.22 (−4.86%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ERNA with… →

ERNA Key Statistics

As of Sep 4, 2026
Trading
Open
$4.50
Previous Close
$4.53
Day's Range
4.21–4.83
52-Week Range
3.18–71.50
Volume
47.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.62
Valuation
Market Cap
$5.03M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.39
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$14.08M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.17M
1-Year Return
−85.87%
Dividend and dates
Avg Volume
470.14K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ERNA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−85.63%
2025−72.41%
2024−83.89%
2023−44.10%
2022−96.14%
2021−6.92%
2020+1.82%
2019+12.82%
2018−53.68%
2017−50.47%
2016 (partial year)+60.68%

As of September 4, 2026.

ERNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$14.08M—
2024$582.00K−$44.54M−7652.7%
2023$68.00K−$21.67M−31864.7%
2022$0.00−$24.58M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$9.32M−$14.08M—
2024$582.00K$486.00K−$17.25M−$44.54M−7652.7%
2023$68.00K−$168.00K−$20.68M−$21.67M−31864.7%
2022$0.00$0.00−$26.95M−$24.58M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ERNA Valuation vs Biotechnology Median

Median of 656 stocks
MetricERNABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Ernexa Therapeutics Inc. (ERNA) is capitalised at $5.03M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 5 employees.

The 52-week range on file runs from $3.18 to $71.50. ERNA last closed at $4.31 on September 4, 2026. That is −$0.22 (−4.86%) against the previous close. The latest close sits 35.53% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Against the prior fiscal year total of $582.00K, that is a change of −100.00%. The same year closed with a net loss of $14.08M. The reported profit margin is 0%. Trailing earnings per share are −0.39.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 2.62. Annualized volatility over the trailing 10 years is 149.72%. The trailing one-year price return is −85.87%. Across 10 years the annualized return works out at −63.66%.

Growth & Income

No dividend is on file for ERNA.

The strongest complete calendar year on file is 2019 at +12.82%; the weakest is 2022 at −96.14%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −85.63% year to date.

Peer Comparison

Ernexa Therapeutics Inc. (ERNA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ernexa Therapeutics Inc. ERNA $5.03M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Ernexa Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Visit website →